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Sorting of lysosomal enzymes
GlcNAc-1-phosphotransferase-phosphotransferase plays a key role in the generation of mannose 6-phosphate
(M6P) recognition markers essential for efﬁcient transport of lysosomal hydrolases to lysosomes. The phos-
photransferase is composed of six subunits (α2, β2, γ2). Theα- and β-subunits are catalytically active and encoded
by a single gene, GNPTAB, whereas the γ-subunit encoded by GNPTG is proposed to recognize conformational
structures common to lysosomal enzymes. Defects in GNPTG cause mucolipidosis type III gamma, which is
characterized by missorting and cellular loss of lysosomal enzymes leading to lysosomal accumulation of storage
material. Using plasmon resonance spectrometry, we showed that recombinant γ-subunit failed to bind the
lysosomal enzyme arylsulfatase A. Additionally, the overexpression of the γ-subunit in COS7 cells did not result in
hypersecretion of newly synthesized lysosomal enzymes expected for competition for binding sites of the
endogenous phosphotransferase complex. Analysis of ﬁbroblasts exhibiting a novelmutation inGNPTG (c.619insT,
p.K207IfsX7) revealed that the expression ofGNPTABwas increasedwhereas inγ-subunit overexpressing cells the
GNPTAB mRNA was reduced. The data suggest that the γ-subunit is important for the balance of
phosphotransferase subunits rather for general binding of lysosomal enzymes.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Newly synthesized soluble lysosomal enzymes are speciﬁcally
modiﬁed in the Golgi apparatus with mannose 6-phosphate (M6P)
residues. In a ﬁrst step, the N-Acetylglucos aminyl-1-phosphotrans-
ferase (termed GlcNAc-1-phosphotransferase, EC 2.7.8.15) transfers
N-Acetylglucosamine-1-phosphate to C6-position of mannose resi-
dues on high-mannose type oligosaccharides using UDP-GlcNAc as
substrate [1,2]. The second step involves the removal of the terminal
GlcNAc to expose the M6P residues by a GlcNAc-1-phosphodiester
N-Acetylglucosaminidase (NAGPA, EC3.1.4.45) residing in the trans-
Golgi network [3]. M6P residues function as recognition marker re-
quired for the M6P receptor mediated transport to lysosomes. Along
the biosynthetic pathway several lysosomal enzymes are proteolyti-
cally modiﬁed leading to mature, active enzymes. Varying amounts of
newly synthesized lysosomal enzymes escape the binding to M6P
receptors in the Golgi and are secreted [4].+49 40 7410 58504.
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complex composed of three subunits (α2β2γ2) [5]. A single gene,
GNPTAB (MIM#607840), encodes the α/β-subunit precursor that
spans the membrane twice [6,7]. It is believed that the α/β-precursor
is proteolytically processed into the individual subunits which seems a
prerequisite for the catalytic activity of the enzyme. The GNPTG gene
(MIM#607838) encodes the γ-subunit (GNPTG) which represents a
soluble glycoprotein of 305 amino acids capable to form disulﬁde-
linked dimers [8]. While it is thought that theα- and β-subunits of the
GlcNAc-1-phosphotransferase comprise the binding sites of the UDP-
GlcNAc substrate, and the catalytic activity [6,9], little is known
about the role of the γ-subunits for the GlcNAc-1-phosphotransferase
complex.
Defective GlcNAc-1-phosphotransferase causes two distinct
human lysosomal storage diseases, mucolipidosis types II and III
(MLII, MIM#252500 and MLIII, MIM#252600, respectively). The
clinically severe MLII (also called I-cell disease) is characterized by a
total loss of GlcNAc-1-phosphotransferase activity and associatedwith
mutations in the GNPTAB gene [6,10–13]. Mutations in the GNPTG
gene are found in patients with MLIII [8,14,15]. However, several
patients clinically diagnosed with MLIII were found to be homozygous
or compound heterozygous for mutations in the GNPTAB gene
[10,11,16] leading to a new classiﬁcation of mucolipidosis type II and
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considering both biochemical and genetic defects [17]. In both MLII
and MLIII patients newly synthesized lysosomal enzymes failed to be
sorted correctly to lysosomes due to the absence or weak equipment
with M6P-residues resulting in lysosomal dysfunction and accumula-
tion of non-degraded material [1].
In this study, we identiﬁed a novel mutation in GNPTG occurring in
homozygosity in a boy with MLIII gamma resulting in a truncated but
stable γ-subunit protein. In vitro and in vivo experiments as well as
quantitative mRNA expression analysis revealed that the γ-subunit
appears to be involved in the regulation of the GlcNAc-1-phospho-
transferase activity rather than the general binding of lysosomal
enzymes.2. Materials and methods
2.1. Reagents and antibodies
Recombinant GNPTG was puriﬁed as a secretory 6His-fusion
protein as described previously [6]. Recombinant arylsulfatase A
(ASA) was produced and puriﬁed as described recently [18].
The reagents were obtained as indicated: Dulbecco's minimal
essential medium (DMEM), Lipofectamine 2000™ from Invitrogen
(Karlsruhe, Germany); fetal calf serum (FCS) from PAA Laboratories
(Pasching, Austria); Chang medium®-In Situ (Irvine Scientiﬁc, Santa
Ana, CA); [35S]-methionine from Perkin Elmer Life Sciences (Boston,
MA); protease inhibitor cocktail and TRI®-Reagent from Sigma-Aldrich
(Deisenhofen, Germany); enhanced chemiluminescence (ECL) reagent
from Pierce (Rockford, IL); Protein Assay from Bio-Rad (Hercules, CA);
Rainbow™ protein marker from Amersham (Buckinghamshire, UK);
Proofstart DNA Polymerase, QIAquick Gel Extraction from Qiagen
(Hilden, Germany); High Capacity cDNA Reverse Transcription Kit and
TaqMan® Gene Expression Assays from Applied Biosystem (Foster
City, CA); Maxima™ Probe qPCR Master Mix, FastRuler™ DNA ladders
and restriction enzymes from Fermentas (St. Leon-Rot, Germany);
Primers were synthesized by MWG Biotech (Munich, Germany).
Polyclonal antibodies against human GNPTG and human cathepsin
D were described previously [15,19]. The monoclonal antibody against
β-tubulin was purchased from the NICHD Developmental Studies
Hybridoma Bank (University of Iowa, IA). Secondary horseradish
peroxidase-conjugated goat anti-rabbit and goat anti-mouse IgG were
obtained from Dianova (Hamburg, Germany).2.2. Cell culture and transfections
COS7 cells were cultured in Dulbecco's modiﬁed Eagle's medium
supplemented with 10% fetal calf serum and antibiotics. Cells were
transfected with myc-GNPTG cDNA using Lipofectamine 2000™
according to manufacturer's instructions and selection was per-
formed with neomycin (0.8 mg/ml). Fibroblasts of four control and
three MLIII gamma patients were maintained in Chang medium®-In
Situ supplemented with antibiotics. MLIII patients 1 and 2 were
homozygous for c.500insC (p.V168Rfs29) and c.347_349delACA
(p.N116del) in GNPTG, respectively and were described previously
[14,15].
Patient 3 was referred for biochemical analysis at the age of
2.5 years on the assumption of mucopolysaccharidosis because of
bone changes (dysostosis) by Dr. Niethammer, Esslingen (Germany).
Due to the deﬁciency of activities of several lysosomal enzymes in
cultured ﬁbroblasts of the patient and grossly elevated lysosomal
activities in the serum (Suppl. Table 1) the diagnosis of mucolipi-
dosis type III was conﬁrmed. The boy is the second child of non-
consanguineous German parents. Today he is 13 years old with nor-
mal intelligence.2.3. Sequencing and mutation analysis
The 11 exons of the GNPTG gene were ampliﬁed by PCR as
described [14]. After separation of the PCR reaction mix by 2% agarose
gel electrophoresis the products were excised and puriﬁed by
QIAquick Gel Extraction Kit. Sequence reactions were performed
with BigDye Terminator Reaction Kit (Applied Biosystems) and
samples were sequenced on an ABI PRISM 377 DNA Sequencer (in
the University Hospital Service Center, Hamburg). The DNA sequences
were compared with published GNPTG sequences (GenBank:
BC014592). Nucleotide numbering was referred to the ATG start
codon, using the A as+1.
2.4. Construction of myc-tagged GNPTG
The expression constructs for myc-GNPTG were generated by PCR
with Proofstart DNA Polymerase using the human GNPTG cDNA as
template and the primers: myc-GNPTG-For: 5′-CACCGAACAAAA-
ACTCATCTCAGAAGAGGATCTGTGAATGGCGGCGGG GCTGGCGCGG-3′
and GNPTG-Rev: 5′-CAAACTCCCACGCAGTCCTGGGTC-3′. The resulting
PCRproductwas cloned into the expressionvector pcDNA3.1D/V5-His-
TOPO® (Invitrogen) according to the manufacturer's instructions. All
constructs were sequenced as described above.
2.5. Surface plasmon resonance spectrometry
The BIAcore sensor chip (Amersham Biosciences) was activated by
N-hydroxy-succinimide and N-ethyl-N′-(dimethyl amino propyl)-
carbodiimide. The coupling of the ligands was carried out in 10 mM
sodium acetate buffer (pH 5.0) with a ligand concentration of 50 μg/ml
and a ﬂow rate of 5 μl/min up to approx. 500 measured RUs on the
sensor chip. Residual binding sites were blocked with 1 M ethanol
amine hydrochloride (pH 8.5). Both ASA and recombinant GNPTG
were used as analytes and as ligands, respectively. The analytes were
solved in degassed and ﬁltered 0.01 M Hepes/OH (pH 7.4), 0.15 M
sodium chloride, 0.005% polysorbate 20 (v/v). The measurements
were carried out with a ﬂow rate of 10 μl/min and an injecting volume
of 75 μl using 250–1000 nM ASA or 400 and 800 nM GNPTG in a
BIAcore 3000 and calculated with the BIAEvaluation® software.
2.6. Metabolic labelling of cells and immunoprecipitation
Metabolic labelling of non-transfected and GNPTG overexpressing
COS7 cells with [35S]-methionine followed by immunoprecipitation of
cathepsin D, SDS-PAGE and ﬂuorography was carried out as described
previously [19]. AIDA software (Raytest, Straubenhardt, Germany) was
used for densitometric evaluation of immunoreactive band intensities.
2.7. Quantitative real-time PCR
Total RNA was isolated from ﬁbroblasts or COS7 cells using the
TRI®-Reagent. For cDNA synthesis 1 μg of total RNA and the High
Capacity cDNA Reverse Transcription Kit were used according to the
manufacturer's instructions. For real-time PCR, TaqMan® Gene
Expression Assays including pre-designed probes and primer set for
human GNPTG (Hs00261332_m1), GNPTAB (Hs00225647_m1) and
NAGPA (Hs00212354_m1) were used. β-Actin was chosen as house
keeping gene (ACTB: Hs9999903_m1). Real-time PCR reactions were
performed as previously described [20]. The relative expression of
analyzed mRNAs was normalized to the level of ACTB mRNA in the
same cDNA sample using the comparative CT method (2−ΔΔCT) [21].
2.8. Other methods
Postnuclear supernatants (PNS) were prepared in 10 mM Tris/HCl
(pH 7.5) containing 250 mM sucrose and protease inhibitor cocktail.
Fig. 2. BIAcore binding analysis between GNPTG and arylsulfatase A. GNPTG was
immobilized to the sensor chip and arylsulfatase A (ASA) passed over the surface at the
indicated concentrations (A). ASAwas immobilized to the sensor chip and the binding of
soluble GNPTG was analyzed (B).
223S. Pohl et al. / Biochimica et Biophysica Acta 1792 (2009) 221–225The cells were homogenized by 25 strokes with a 17-gauge needle
on ice. After centrifugation at 1000 g PNS were used for measurement
of protein content by the Protein Assay reagent. Aliquots of PNS
(25–75 μg protein) were separated by SDS-PAGE and blotted onto
nitrocellulose. After blocking with 5% (w/v) non-fat dry milk in
phosphate-buffered saline containing 0.1% (v/v) Tween-20, the
membrane was incubated either with anti-human GNPTG antibody
(1:250) or anti β-tubulin (1:1000) overnight followed by incuba-
tion with respective secondary horseradish peroxidase-conjugated
IgG (1:10,000) in the same buffer. The immunoreactive bands were
visualized by enhanced chemiluminescence. The activities of the
lysosomal enzymes in cell extracts and media were determined as
described previously [15] and lysosomal enzymes activities in the
patient's serum as detailed elsewhere [16].
3. Results
3.1. Identiﬁcation of a novel mutation in the GNPTG gene in an MLIII
gamma patient
The clinical and biochemical ﬁndings of patient 3 were compatible
with the diagnosis of mucolipidosis type III. The activities of several
lysosomal enzymes were increased in the serum (Suppl. Table 1). In
cultured ﬁbroblasts residual lysosomal enzyme activities varied
between 8% (β-hexosaminidase, α-mannosidase) and 47% (galacto-
cerebrosidase) of control cells. To examine whether the γ-subunit of
the GlcNAc-1-phosphotransferase (GNPTG) was defective, the gene
was sequenced in genomic DNA of the patient. A novel homozygous
nucleotide insertion in exon 9 (c.619insT) was identiﬁed leading to a
frameshift and to a premature stop codon after 7 new amino acids
followed by the substituted Lys-207 residue (p.K207IfsX7). Western
blot analysis showed that in cell extracts of patient 3 ﬁbroblasts a
24 kDa immunoreactive polypeptide was detectable whereas control
cells expressed an immunoreactive polypeptide with the predicted
molecularmass of 34 kDa of the GNPTGmonomer (Fig.1A). In contrast
to the abundant truncated GNPTG protein, the relative GNPTG mRNA
expression was 3-fold reduced compared with control cells (Fig. 1B).
The mRNA expression of GNPTG was also 2- and 5-fold decreased in
two other cell lines from MLIII gamma patients 1 and 2 with mutant
GNPTG (Fig. 1B).
3.2. Compensatory gene expression in GNPTG-defective cells
To examine whether defects in the GNPTG gene affect the
expression of other components involved in M6P formation, theFig. 1. GNPTG expression in ﬁbroblasts of MLIII gamma patient 3. Western blot analysis
of GNPTG in control (Co) and MLIII gamma patient 3 (P3) ﬁbroblasts. The positions of
molecular mass markers are indicated. The content of β-tubulin in the samples served
as control for equal loading (A). GlcNAc-1-phosphotransferase and phosphodiesterase
gene expression in MLIII gamma ﬁbroblasts. The relative levels of GNPTG, GNPTAB, and
NAGPA mRNA expression were determined in ﬁbroblasts of MLIII gamma patients by
real-time PCR normalized to β-actin expression. The relative mRNA expression in
control ﬁbroblasts was set 1. Analysis of four control and ﬁbroblasts of MLIII patients 1, 2
and 3 are themean of triplicate PCRs obtained from two independent RNA preparations.
Data are expressed as the mean fold change in respective gene expression ±SD (B).mRNA levels of GNPTAB and NAGPAwere determined in ﬁbroblasts of
the MLIII gamma patients. In MLIII gamma cell lines of patients 1, 2
and 3 the relative expression of both GNPTAB and NAGPA was 1.5- to
2.5-fold increased in comparison with the expression of four control
cells (Fig. 1B).3.3. GNPTG of the GlcNAc-1-phosphotransferase failed to bind
arylsufatase A and cathepsin D
It is believed that the α/β-subunits (GNPTAB) of GlcNAc-1-
phosphotransferase exhibit enzymatic activity whereas the γ-subunit
(GNPTG) is responsible for binding of lysosomal enzymes [1]. To
examine whether GNPTG is capable to bind lysosomal enzymes,
surface plasmon resonance spectroscopy was used. Monomeric and
dimeric forms of GNPTG were immobilized on the sensor chip, and
recombinant arylsulfatase A (ASA) was passed over the surface
(Fig. 2A). After completion of analyte (ASA) injection, buffer change
leads to detachment of the analyte indicating that ASA does not bind
to immobilized GNPTG. Similarly, GNPTG failed to bind to immobilized
ASA on the sensor surface, independently of analyte concentrations
(Fig. 2B).
In a second approach the capability of GNPTG to function in the
recognition of lysosomal enzymes was studied in vivo. GNPTG was
stably overexpressed in COS7 cells to examinewhether it can compete
with the endogenous GlcNAc-1-phosphotransferase complex for
binding of newly synthesized lysosomal enzymes. Subsequently the
formation of M6P residues should be reduced which should lead to
missorting of newly synthesized lysosomal enzymes into the medium
and decreased enzymatic activities of intracellular lysosomal hydro-
lases. Western blot analysis showed the expression of a 36 kDa
immunoreactive polypeptide, which was weakly detectable in non-
transfected COS7 cells (Fig. 3A). Real-time PCR analyses revealed that
the GNPTG mRNA levels in the transfected cells were approximately
28-fold higher than in non-transfected cells (Fig. 3B). The expression
Fig. 4. Biosynthesis and sorting of the lysosomal enzyme cathepsin D in GNPTG
overexpressing cells. Non transfected (−) and GNPTG (+) stably transfected cells were
labelled with [35S]-methionine for 1 h and either harvested (−) or chased (+) for 4 h,
followed by immunoprecipitation of cathepsin D from cell extracts and media,
separated by SDS-PAGE (10% acrylamide), and visualized by ﬂuorography. The precursor
andmature form of cathepsin D and the positions of molecular mass markers in kDa are
indicated. The amounts of secreted cathepsin D precursors were determined by
densitometry and are expressed as percentage of total synthesized cathepsin D. A
representative ﬂuorograph out of three independent experiments is shown.
Fig. 3. Stable overexpression of GNPTG. Western blot analysis of GNPTG in extracts of
non-transfected (−) and GNPTG expressing (+) COS7 cells. The positions of molecular
mass markers are indicated. Equal loading is demonstrated by β-tubulin immunostain-
ing (A). The relative GNPTG, GNPTAB and NAGPA mRNA level were determined in non-
transfected and COS7 cells stably expressing GNPTG by real-time PCR and normalized to
β-actinmRNA expression. Data are the mean of triplicate PCRs obtained from three RNA
preparations and expressed as the fold change ±SD (B).
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cells whereas the level of NAGPA mRNA was not affected (Fig. 3B).
Next, the transport and sorting of the newly synthesized lysosomal
enzyme cathepsin D was examined in GNPTG overexpressing COS7
cells. Cells were labelled for 1 h with [35S]-methionine and either
harvested or chased for further 4 h in non-radioactive media followed
by immunoprecipitation of cathepsin D from cell extracts and media.
After pulse-labelling, themajority of cathepsin D could be precipitated
as a 53 kDa precursor protein, and only small amounts of a 31 kDa
immunoreactive polypeptide were detectable (Fig. 4). During the
chase period both in non-transfected and in GNPTG overexpressing
cells the cathepsin D precursor polypeptide was completely pro-
cessed to the mature form. Under these conditions 17 and 23% of
the newly synthesized cathepsin D precursor were secreted into the
media (Fig. 4). Furthermore, in comparison with non-transfected
cells we found no differences in activities of the lysosomal enzymes
β-hexosaminidase, β-glucuronidase, and ASA in cells and media of
GNPTG overexpressing COS7 cells (Suppl. Table 2). The data suggest
that GNPTG failed to bind at least the lysosomal enzymes ASA,
cathepsin D, β-hexosaminidase, and β-glucuronidase.
4. Discussion
In the present study the importance of the γ-subunit of the
GlcNAc-1-phosphotransferase (GNPTG) for the binding of lysosomal
enzymes was analyzed. The GlcNAc-1-phosphotransferase complex
have to exhibit three binding sites for i) the phosphate donor UDP-
GlcNAc, ii) the high-mannose type oligosaccharides on lysosomal
enzymes that have to be equipped with M6P residues, and iii) the
speciﬁc binding site for lysosomal proteins. Due to the similarities to
bacterial capsule biosynthesis proteins it has been proposed that
the N-terminal domain of the α-subunit comprises the nucleotide
sugar binding site [6]. Both α- and β-subunits exhibit catalytic acti-
vity sufﬁcient for phosphorylation of small acceptor molecules such as
α-methyl mannoside [9]. The transfer of GlcNAc-1-phosphate to
lysosomal enzymes as acceptors, however, was shown to require the
presence of intact γ-subunits [22,23]. From these data it has been
concluded that the γ-subunit (GNPTG) of the GlcNAc-1-phospho-transferase complex is responsible for the recognition of lysosomal
enzymes [1].
To determine the role of GNPTG in recognition and binding of
lysosomal enzymes, two complementary approaches were utilized.
First, surface plasmon resonance spectrometry showed that immobi-
lized GNPTG did not bind the puriﬁed lysosomal enzyme ASA.
Additionally, the immobilized ASA failed to interact with GNPTG. In
the second experimental approach we examined whether the over-
expression of the soluble γ-subunit is capable to compete with the
endogenous GlcNAc-1-phosphotransferase complex in vivo during the
process of phosphorylation of lysosomal proteins. If GNPTG would
function in recognition of lysosomal hydrolases, its overexpression
should impair sorting which subsequently results in hypersecretion of
newly synthesized lysosomal enzymes into media. Because we have
neither observed an increase in the secretion of metabolically labelled
cathepsin D nor in the activities of three lysosomal enzymes in the
media of GNPTG overexpressing cells, we hypothesize that GNPTG
lacks the capability to bind to a conformation-dependent recognition
domain present on the surface of many different lysosomal enzymes
[24–28]. This hypothesis is supported by our previous studies
demonstrating that no lysosomal enzymes could be eluted from a
GNPTG afﬁnity matrix [6]. Finally, using brain tissues of mice deﬁcient
for GNPTG, Kornfeld and colleagues showed recently [29] that the
modiﬁcation of lysosomal enzymes with M6P residues was not
generally prevented but that certain hydrolases, e.g. α-mannosidase
and β-glucuronidase, were phosphorylated considerably better than
others such as β-mannosidase and β-galactosidase. We cannot,
however, exclude that GNPTG recognizes lysosomal enzymes only
when it is associated with GNPTAB. Such a function would neither be
detected in the BIAcore experiments nor in the GNPTG overexpression
experiments.
The analysis of ﬁbroblasts of three MLIII patients with mutations in
the GNPTG gene in this study, has provided new data on regulatory
functions of GNPTG in the process of the formation of the M6P
recognition marker. In all three MLIII cell lines the relative GNPTG
mRNA levels were reduced between 25 and 60%. The mutant GNPTG
proteins of at least patient 2 (p.N116del [15] and patient 3 (p.
K207IfsX7; Fig. 1A) could be detected by Western blotting and
appeared to be resistant to ER-associated degradation processes. In
these ﬁbroblasts the relative mRNA expression of the genes encoding
the α/β-subunits precursors of GlcNAc-1-phosphotransferase
(GNPTAB) and the phosphodiesterase (NAGPA) were found to be
upregulated. While the lack of speciﬁc antibodies does not allow
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the data suggest that compensatory mechanisms might prevent the
complete missorting of newly synthesized lysosomal enzymes.
Similarly, the overexpression of GNPTG in COS7 cells appears to
induce a down-regulation of GNPTAB (Fig. 3B). The compensatory
mechanisms of GNPTG/GNPTABmRNA expression and their role in the
ﬁne regulation of the formation of the M6P recognition marker are
unclear and require further studies.
The novel mutation identiﬁed in MLIII gamma patient 3 leads to a
frameshift and premature termination of translation, p.K207IfsX7. A
total of eight distinct mutations in GNPTG have been described inMLIII
gamma patients of different ethnic background [8,14,15]. The detailed
biochemical and molecular analysis of ﬁbroblasts of these patients is
essential and represents important and unique sources for investigat-
ing the mechanism of phosphorylation of lysosomal enzymes and
functional correlations to the genotype.
Together, the data suggest evidence that the γ-subunit of GlcNAc-
1-phosphotransferase is not involved in binding of newly synthesized
lysosomal enzymes during the phosphorylation of their oligosacchar-
ide chains. In ﬁbroblasts of patients with MLIII gamma the expression
of α/β-precursor subunits of GlcNAc-1-phosphotransferase and the
uncovering enzyme appears to be altered in a compensatory manner
through yet unknown mechanisms.
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